Translate Bio, Inc. Gains 71.98%

Thu, Sep 26, 2024 at 07:35 PM

Translate Bio, Inc. (TBIO:NASDAQ) jumped higher at $3.99, representing a gain of 72%. On Thu, Sep 26, 2024, TBIO:NASDAQ touched a New 2-Week High of $3.99. The stock got featured on our News Catalysts scanner on Wed, Sep 25, 2024 at 06:09 PM in the 'PATNERSHIP' category. From Thu, Sep 12, 2024, the stock recorded 40.00% Up Days and 36.36% Green Days

The stock spiked on Thu, Sep 19, 2024 at $5.17 with a volume of 53M+.

About Translate Bio, Inc. (TBIO:NASDAQ)

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Top 10 Gainers:

Fangdd Network Group Ltd. (DUO:NASDAQ), 109.97%
Tempo Automation Holdings Inc. (TMPO:NASDAQ), 84.62%
Volato Group Inc. Class A (SOAR:NYSEMKT), 83.21%
Translate Bio, Inc. (TBIO:NASDAQ), 71.98%
Alpha Technology Group Limited (ATGL:NASDAQ), 71.16%
Pasithea Therapeutics Corp. (KTTA:NASDAQ), 52.15%
Calithera Biosciences, Inc. (CALA:NASDAQ), 50%
CN Energy Group Inc. (CNEY:NASDAQ), 39.73%
Nano Labs Ltd (NA:NASDAQ), 33.53%
American Lithium Corp. (AMLI:NASDAQ), 33.33%